Chromosomal DNA in autologous CD34+ hematopoietic stem cells (CD34+ HSC DNA)

Chromosomal DNA in autologous CD34+ hematopoietic stem cells (HSCs) is the genomic material within a patient's own blood-forming progenitor cells, serving as the fundamental target for ex vivo gene therapies. CD34+ HSCs are defined by their ability to self-renew and differentiate into all mature blood lineages, making them an ideal vehicle for permanent genetic correction (NIH, 2023). By modifying the DNA within these cells—either through the insertion of functional gene copies using lentiviral vectors or the precise editing of endogenous sequences using CRISPR-Cas9—clinicians can treat a variety of monogenic hematologic and metabolic disorders (FDA, 2023). Once the modified cells are re-infused into the patient following a conditioning regimen, they engraft in the bone marrow and produce a continuous supply of healthy blood cells (Nature, 2022). This autologous approach significantly reduces the risk of immunological rejection and graft-versus-host disease compared to allogeneic transplantation (NEJM, 2021). However, the therapy carries risks such as insertional mutagenesis and off-target effects, which require long-term monitoring of the patient's genomic stability.

Other names

Autologous CD34+ cell genomeGenomic DNA of hematopoietic stem cellsHSC chromosomal DNACD34+ hematopoietic progenitor cell DNA

Ex vivo genetic modification of hematopoietic stem cells through viral vector-mediated gene addition or CRISPR-Cas9-mediated gene editing to restore physiological function or compensate for genetic mutations.